Welcome to our dedicated page for Protagonist Ther SEC filings (Ticker: PTGX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Decoding Protagonist Therapeutics鈥� (PTGX) filings鈥攔ich with peptide-science jargon, cash-runway disclosures, and collaboration milestones鈥攃an be overwhelming. Whether you鈥檙e scanning a sudden 8-K or tracing capital raises, the information you need hides in technical detail. That鈥檚 why investors search for 鈥渦nderstanding Protagonist Therapeutics SEC documents with AI鈥� and 鈥淧rotagonist Therapeutics SEC filings explained simply.鈥�
Stock Titan turns that challenge into clarity. Our platform delivers AI-powered summaries that highlight trial updates, partnership economics, and risk factors inside every Protagonist Therapeutics annual report 10-K simplified, each Protagonist Therapeutics quarterly earnings report 10-Q filing, and even the briefest Protagonist Therapeutics 8-K material events explained. AG真人官方-time alerts flag Protagonist Therapeutics Form 4 insider transactions real-time, so you never miss new Protagonist Therapeutics executive stock transactions Form 4. Need detail? Click into a filing and our expert notes walk you straight to cash-position tables, IL-23 program costs, or board-level pay disclosures from the Protagonist Therapeutics proxy statement executive compensation section.
Use these insights to act faster: compare revenue from milestone payments with R&D burn in our Protagonist Therapeutics earnings report filing analysis; monitor Protagonist Therapeutics insider trading Form 4 transactions ahead of data readouts; or archive every disclosure for audits. With comprehensive coverage of all forms鈥�10-K, 10-Q, 8-K, S-3, Schedule 13G鈥攁nd continuous EDGAR updates, Stock Titan equips you to follow this clinical-stage biotech鈥檚 journey from lab bench to commercial launch, without wading through hundreds of pages on your own.
Protagonist Therapeutics (PTGX) Form 4: President & CEO Dr. Dinesh V. Patel settled 25,000 performance stock units on 07/21/25 at a cost basis of $0 after the company met pre-set corporate objectives.
To cover related tax obligations, 12,859 shares were immediately sold at a weighted-average price of $54.86. Additional discretionary sales followed: 22,065 shares on 07/22/25 at $55.05 and 17,520 shares on 07/23/25 at $54.79. In total, 52,444 shares were sold for gross proceeds of roughly $2.9 million, trimming Patel鈥檚 direct ownership from 583,462 to 531,018 shares鈥攁 reduction of about 9%.
No derivative transactions were reported. While the PSU vesting signals successful execution of 2021-vintage performance goals, the scale of secondary sales may draw investor attention to potential insider-sentiment shifts. Patel remains both a director and the largest named executive insider holder.
Protagonist Therapeutics, Inc. (PTGX) filed a Form 144 indicating an intended sale of 50,000 common shares through J.P. Morgan Securities on or after 22 Jul 2025. The shares were acquired via six option exercises between Feb 2020 and Mar 2024 and represent roughly 0.08 % of the 61.98 million shares outstanding. The planned transaction carries an aggregate market value of about $2.76 million based on the filing鈥檚 reference price. No prior sales were reported in the past three months, and the filer affirmed awareness of no undisclosed material adverse information. While Form 144 only signals intent鈥攏ot certainty鈥攐f sale, it provides investors with advance notice of potential insider liquidity activity.
Protagonist Therapeutics (NASDAQ:PTGX) filed an 8-K reporting the final voting results of its 2025 Annual Meeting held on June 20, 2025.
- Directors elected: Harold E. Selick, Ph.D. (44.8 M for / 9.2 M withheld) and Bryan Giraudo (42.5 M for / 11.5 M withheld) to serve until 2028.
- Say-on-Pay: Executive compensation approved with 50.8 M votes for (92.6% of votes cast).
- Auditor ratification: Ernst & Young LLP confirmed with 55.5 M votes for (99.1%).
No other matters were brought before shareholders, and the meeting produced routine outcomes with no material corporate changes.
FAQ
What is the current stock price of Protagonist Ther (PTGX)?
What is the market cap of Protagonist Ther (PTGX)?
What is the core focus of Protagonist Therapeutics?
What differentiates their approach to drug development?
Which key therapeutic candidates are in their pipeline?
How does Protagonist generate revenue?
What are the strategic collaborations that support its development efforts?
How does the company's technology platform enhance its drug candidates?
What clinical conditions are being targeted by its products?
How does Protagonist position itself in the competitive biopharmaceutical landscape?
